Divis Lab: GLP-1 opportunity to unfold in the medium term

Anubhav Sahu • December 24, 2024 / 09:25 IST

Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

Strong custom synthesis growth visibility

To read the full story,

Subscribe to Moneycontrol PRO

Ad-free Experience
Access Exclusive Stories
Weekly Investment Ideas
Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Divis Lab: GLP-1 opportunity to unfold in the medium term

Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.

What Do You Get